Outlook Therapeutics

-$0.01 (-0.42%) As of 4:48 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

CEO
C. Russell Trenary
Employees
8
Headquarters
Iselin, New Jersey
Founded
2010

OTLK Key Statistics

Market Cap
418.38M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
695.61K
High Today
$2.42
Low Today
$2.34
Open Price
$2.36
Volume
354.93K
52 Week High
$4.26
52 Week Low
$0.6305

OTLK Earnings

-$0.62
-$0.41
-$0.21
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Dec 22, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure